Skip to main content

Table 3 Clinical symptomatology reported by the 9 HHT patients with ascertained SarsCov-2 infection

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

COVID-19, ascertained (n = 9)
Age years-old, mean (SD) 46.22 ± 9.55
 Range 35–65
Gender (Female), n (%) 3 (33.3)
Clinical symptomatology, COVID-19
Fever, n (%) 7/9 (77.8)
Coughing, n (%) 4/9 (44.4)
Headache, n (%) 2/9 (22.2)
Dyspnea, n (%) 4/9 (44.4)
Muscular Pain, n (%) 3/9 (33.3)
Sense of Tiredness/Fatigue, n (%) 5/9 (55.5)
Diarrhoea, n (%) 2/9 (22.2)
Sore Throat, n (%) 2/9 (22.2)
Rhinorrhea, n (%) 0/9
Conjunctivitis, n (%) 0/9
Gustative/olfactory sensory impairment, n (%) 3/9 (33.3)
None (Asymptomatic), n (%) 1/9 (11.1)
Clinical management and outcomes, COVID-19
Rx-confirmed Pneumoniaa, n (%) 4/9 (44.4)
Domiciliar management, n (%) 7/9 (77.8)
Oxygen support therapy at domiciliar regimen, n (%) 0/9
Hospitalization required, n (%) 2/9 (22.2)
Non-invasive ventilation, n (%) 1/9 (11.1)
Invasive ventilation (intubation), n (%) 1/9 (11.1)
Death, n (%) 0/9
  1. aChest radiological investigation was performed in 4 patients only